IDH mutation in glioma: molecular mechanisms and potential therapeutic targets.

Han S, Liu Y, Cai SJ, Qian M, Ding J, Larion M, Gilbert MR, Yang C. · 2020

Read IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. by Han S, Liu Y, Cai SJ, Qian M, Ding J, Larion M, Gilbert MR, Yang C. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7250901.txt.

Introduction

Han and co-authors review gene faults in IDH enzymes in glioma, a brain tumor. Their review appeared in the British Journal of Cancer. IDH enzymes help cells make energy and keep chemical balance. Faults in their genes occur in most lower-grade gliomas. They also occur in some blood, bile duct and cartilage cancers.

Mutant IDH gains a new job. It makes a substance called D-2-hydroxyglutarate, which builds up in tumor cells. That buildup reshapes cell metabolism and gene control. It also affects how tumors resist treatment. Patients with the fault often live longer than those without it. New targeted drugs are being developed against the mutant enzymes.

Catalog record

CREATORHan S, Liu Y, Cai SJ, Qian M, Ding J, Larion M, Gilbert MR, Yang C.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE65 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7250901

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets By Sue Han, Yang Liu, Sabrina J. Cai, Mingyu Qian, Jianyi Ding, Mioara Larion, Mark R. Gilbert, Chunzhang Yang Published in: British Journal of Cancer DOI: 10.1038/s41416-020-0814-x ABSTRACT Isocitrate dehydrogenase (IDH) enzymes catalyse the oxidative decarboxylation of isocitrate and therefore play key roles in the Krebs cycle and cellular homoeostasis. Major advances in cancer genetics over the past decade have revealed that the genes encoding IDHs are frequently mutated in a variety of human malignancies, including gliomas, acute myeloid leukaemia, cholangiocarcinoma, chondrosarcoma and thyroid carcinoma. A series of seminal studies further elucidated the biological impact of the IDH mutation and uncovered the potential role of IDH mutants in oncogenesis. Notably, the neomorphic activity of the IDH mutants establishes distinctive patterns in cancer metabolism, epigenetic shift and therapy resistance. Novel molecular targeting approaches have been developed to improve the efficacy of therapeutics against IDH-mutated cancers. Here we provide an overview of the latest findings in IDH-mutated human malignancies, with a focus on glioma, discussing unique biological signatures and proceedings in translational research. BACKGROUND Isocitrate dehydrogenase (IDH) enzymes, of which there are three isoforms, are essential enzymes that participate in several major metabolic processes, such as the Krebs cycle, glutamine metabolism, lipogenesis and redox regulation.1–3 IDH1 is located in the cytoplasm and peroxisomes, whereas IDH2 and IDH3 are located in the mitochondrial matrix.4 The catalytic sites of IDH1 and IDH2 exhibit affinity for the substrate, isocitrate, together with nicotinamide adenine dinucleotide phosphate (NADP+) and a divalent metal cation, usually magnesium or manganese,5 resulting in the formation of α-ketoglutarate (α-KG). IDH3, which also catalyses the transformation from isocitrate into α-KG, employs nicotinamide adenine dinucleotide (NAD+) as its cofactor. The catalytic activity of IDH requires homodimerisation along with an alteration in the enzyme conformation; isocitrate binding changes the structure of the enzyme from an open to a closed conformation.6 Substrate recognition depends on the amino acid residues in the active site, whereas the frequent mutated active site residue in cancer is arginine 132 (R132).5 Mutations in IDH are prevalent in human malignancies. In glioma, IDH mutations are recognised in >80% of World Health Organisation (WHO) grade II/III cases.7 In WHO grade IV glioblastoma (GBM), IDH mutations are also found frequent in secondary GBM, which account for 73% of clinical cases, whereas they are less seen in primary GBM (3.7%).8 A follow-up investigation showed that the presence of IDH mutations predict a favourable disease outcome with prolonged median survival in GBM (IDH wild type: 15 months; IDH mutant: 31 months) and anaplastic astrocytoma (IDH wild type: 20 months; IDH mutant: 65 months).7 Although IDH-mutated glioma generally exhibits a better disease outcome, the high incidence of IDH mutations in secondary GBM suggests that lower-grade glioma with IDH mutation often recur with having undergone malignant transformation to a higher grade. In addition, IDH-mutated glioma is more likely to develop a hypermutation phenotype, which is associated with worsened prognosis.9 In non-central nervous system (non-CNS) malignancies, IDH mutations are identified in acute myeloid leukaemia (AML; 16% among all clinical cases),10 intrahepatic cholangiocarcinoma (23% among all clinical cases)11 and central/periosteal chondrosarcoma (56% among all clinical cases).12 The investigation of these non-CNS tumours with similar IDH mutation provides valuable information for glioma research, whereas in the present review we tend to be focussed on IDH-mutated glioma. IDH mutations that are associated with cancer tend to localise to the arginine residue that is crucial for the recognition of isocitrate (R132 for IDH1, R140 or R172 for IDH2).7 Missense mutations in the IDH1 gene result in the replacement of a strong, positively charged arginine residue at position 132 with lower-polarity amino acids such as histidine (H), lysine (K) or cysteine (C), which impedes the formation of hydrogen bonds with the α-carboxyl and β-carboxyl sites of isocitrate.13,14 The mutant IDH enzyme therefore exhibits decreased affinity for isocitrate, along with an elevated preference for NADPH. However, only one copy of the IDH gene is mutated in tumours and, in tumour cells harbouring heterozygous IDH mutations, the main forms of IDH dimers are presumed to be heterodimers that contain a version of wild-type IDH1 and a version with the R132H mutation. As a result, in IDH-mutant cells, the IDH1 wild-type component of the dimer converts isocitrate into α-KG to produce NADPH, whereas the mutant part of the dimer exhibits neomorphic activity, converting α-KG into D-2-hydroxyglutarate (D-2-HG) in an NADPH-dependent manner (Fig. 1).15Fig. 1Dimerisation of IDH1.Two wild-type IDH1 monomers form a catalytic homodimer, which transforms isocitrate into α-KG. In IDH1-mutated cells, a catalytic heterodimer is formed with one wild-type monomer and one monomer carrying the R132H mutant. The heterodimer exhibits neomorphic activity, which consumes α-KG for D-2-HG synthesis. Biochemical studies indicate that a homodimer formed by two IDH1 mutant monomer is not catalytically active. Molecular modelling is based on the published crystal structures 1T09,6 3MAS and 3MAP.111 The establishment of neomorphic activity associated with the IDH mutation has long been shown to have an effect on cellular metabolism, cancer biology and oncogenesis.16,17 In this review, we will outline the biological impact of IDH-mutant neomorphic activity on cellular metabolism, epigenetic regulation and redox homoeostasis and address key advances in the cancer biology of IDH-mutated glioma and the implication of these findings in the development of future therapeutics, with a particular focus on glioma. Key findings from other IDH-mutated tumour models, such as AML and cholangiocarcinoma, will also be discussed, as they provide additional insights into the molecular mechanisms in IDH-mutated glioma. THE BIOLOGICAL IMPACT OF IDH-MUTANT NEOMORPHIC ACTIVITY Metabolic reprogramming IDH-mutant enzymes cause the accumulation of D-2-HG at concentrations as high as 5–30 mM15 in the cytoplasm, thereby draining carbohydrates from the Krebs cycle.18 The Krebs cycle is adjusted to compensate for fluctuations in the metabolic pathways.19 A 13C metabolic flux analysis suggested that IDH1-mutated cells exhibit increased oxidative metabolism in the Krebs cycle, whereas reductive glutamine metabolism is suppressed.20 With the depletion of cellular metabolism, several non-Krebs-cycle sources of carbohydrates are recruited to compensate for the loss of α-KG.21,22 Waitkus et al.23 demonstrated that glutamate dehydrogenase 2, an enzyme that catalyses the conversion of glutamate into α-KG and that is expressed at high levels in the brain, is important for relieving the metabolic liabilities in the context of IDH mutants. This finding is confirmed by the observation that IDH-mutated glioma cells are more sensitive to the inhibition of glutaminase,24 suggesting that glutaminolysis serves as a key compensatory pathway to maintain metabolic homoeostasis. McBrayer et al.25 further highlighted the dependency of IDH1-mutated cells on glutaminolysis, as D-2-HG functions as an inhibitor of the branched-chain amino acid transaminase (BCAT1/2), thereby decreasing the levels of glutamate. Furthermore, the consumption of NADPH by IDH mutants compromises de novo lipogenesis, resulting in an increased dependence on exogenous lipid sources for cellular growth.2 This is accompanied by the stimulation, by D-2-HG, of glutamine-derived lipogenesis under hypoxic condition to meet the needs for lipid productivity.26 Lactate dehydrogenase A (LDHA) catalyses the transformation of pyruvate formed by glycolysis into L-lactate,27 and the expression of LDHA is thus considered to be a hallmark of Warburg phenotype, allowing rapid glycolytic flux to meet the demands for cellular proliferation.28 Although LDHA is highly expressed in a variety of

Read the complete text